Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID	DTD0247 Transporter Info
Gene Name	SLC29A1
Transporter Name	Equilibrative nucleoside transporter 1
Gene ID	2030
UniProt ID	Q99808

Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)
Chemical Compound
DT Modulation1	Cilostazol inhibits the reaction SLC29A1 protein results in increased uptake of Adenosine			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Dipyridamole inhibits the reaction SLC29A1 protein results in increased uptake of Adenosine			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	draflazine inhibits the reaction SLC29A1 protein results in increased uptake of Adenosine			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Ethanol promotes the reaction SLC29A1 protein alternative form results in increased uptake of Adenosine			[54]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Ethanol promotes the reaction SLC29A1 protein results in increased uptake of Adenosine			[54]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	SLC29A1 protein alternative form results in increased uptake of Adenosine			[54]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	SLC29A1 protein results in increased uptake of Adenosine			[54]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	Ticagrelor inhibits the reaction SLC29A1 protein results in increased uptake of Adenosine			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Dipyridamole inhibits the reaction 4-nitrobenzylthioinosine binds to SLC29A1 protein			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Dipyridamole inhibits the reaction SLC29A1 protein results in increased uptake of Adenosine			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Dipyridamole inhibits the reaction SLC29A1 protein results in increased uptake of Uridine			[50]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Dipyridamole promotes the reaction 4-nitrobenzylthioinosine inhibits the reaction SLC29A1 protein co-treated with SLC29A2 protein results in increased uptake of Uridine			[48]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Dipyridamole results in decreased activity of SLC29A1 protein			[75]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Lidoflazine inhibits the reaction SLC29A1 protein results in increased uptake of Uridine			[82]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	4-nitrobenzylthioinosine inhibits the reaction SLC29A1 protein results in decreased susceptibility to Fluorouracil			[49]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Fluorouracil promotes the reaction SLC29A1 protein results in increased uptake of Gemcitabine			[26]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	SLC29A1 protein affects the susceptibility to Fluorouracil			[79]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	SLC29A1 protein results in decreased susceptibility to Fluorouracil			[49]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Testosterone co-treated with Calcitriol results in decreased expression of SLC29A1 mRNA			[9]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Testosterone co-treated with Calcitriol results in decreased expression of SLC29A1 mRNA			[9]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Tretinoin co-treated with Arsenic Trioxide results in increased expression of SLC29A1 mRNA			[60]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Tretinoin results in increased expression of SLC29A1 mRNA			[60]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased expression of SLC29A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Cisplatin co-treated with jinfukang results in increased expression of SLC29A1 mRNA			[37]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Cisplatin results in increased expression of SLC29A1 mRNA			[37]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	SLC29A1 protein affects the susceptibility to Cisplatin			[68]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	SLC29A1 protein affects the susceptibility to Doxorubicin			[76]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Estradiol co-treated with TGFB1 protein results in increased expression of SLC29A1 mRNA			[77]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	4-nitrobenzylthioinosine inhibits the reaction SLC29A1 protein co-treated with SLC29A2 protein results in increased uptake of Uridine			[48]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	4-nitrobenzylthioinosine inhibits the reaction SLC29A1 protein results in increased uptake of Uridine			[50]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Dilazep inhibits the reaction SLC29A1 protein results in increased uptake of Uridine			[50]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Dipyridamole inhibits the reaction SLC29A1 protein results in increased uptake of Uridine			[50]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Dipyridamole promotes the reaction 4-nitrobenzylthioinosine inhibits the reaction SLC29A1 protein co-treated with SLC29A2 protein results in increased uptake of Uridine			[48]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Lidoflazine inhibits the reaction SLC29A1 protein results in increased uptake of Uridine			[82]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	SLC29A1 protein co-treated with SLC29A2 protein results in increased uptake of Uridine			[48]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	SLC29A1 protein results in increased uptake of Uridine			[48]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Ticagrelor inhibits the reaction 4-nitrobenzylthioinosine binds to SLC29A1 protein			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Ticagrelor inhibits the reaction SLC29A1 protein results in increased uptake of Adenosine			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone results in increased expression of SLC29A1 mRNA			[27]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Selenium co-treated with Vitamin E results in increased expression of SLC29A1 mRNA			[28]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Benzo(a)pyrene affects the methylation of SLC29A1 5' UTR			[61]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Benzo(a)pyrene results in increased methylation of SLC29A1 promoter			[61]
Regulation Mechanism				Transcription Factor Info
1-Methyl-4-phenylpyridinium	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	1-Methyl-4-phenylpyridinium results in increased expression of SLC29A1 mRNA			[34]
Regulation Mechanism				Transcription Factor Info
2,3-bis(3'-hydroxybenzyl)butyrolactone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone results in increased expression of SLC29A1 mRNA			[27]
Regulation Mechanism				Transcription Factor Info
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid results in decreased expression of SLC29A1 mRNA			[36]
Regulation Mechanism				Transcription Factor Info
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased expression of SLC29A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
4-nitrobenzylthioinosine	10 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	4-nitrobenzylthioinosine binds to SLC29A1 protein			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	4-nitrobenzylthioinosine inhibits the reaction SLC29A1 protein co-treated with SLC29A2 protein results in increased uptake of Uridine			[48]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	4-nitrobenzylthioinosine inhibits the reaction SLC29A1 protein results in decreased susceptibility to Fluorouracil			[49]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	4-nitrobenzylthioinosine inhibits the reaction SLC29A1 protein results in increased uptake of Gemcitabine			[49]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	4-nitrobenzylthioinosine inhibits the reaction SLC29A1 protein results in increased uptake of Uridine			[50]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Cilostazol inhibits the reaction 4-nitrobenzylthioinosine binds to SLC29A1 protein			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	Dipyridamole inhibits the reaction 4-nitrobenzylthioinosine binds to SLC29A1 protein			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	Dipyridamole promotes the reaction 4-nitrobenzylthioinosine inhibits the reaction SLC29A1 protein co-treated with SLC29A2 protein results in increased uptake of Uridine			[48]
Regulation Mechanism				Transcription Factor Info
DT Modulation9	draflazine inhibits the reaction 4-nitrobenzylthioinosine binds to SLC29A1 protein			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation10	Ticagrelor inhibits the reaction 4-nitrobenzylthioinosine binds to SLC29A1 protein			[47]
Regulation Mechanism				Transcription Factor Info
abrine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	abrine results in decreased expression of SLC29A1 mRNA			[51]
Regulation Mechanism				Transcription Factor Info
Acrolein	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone results in decreased expression of SLC29A1 mRNA			[52]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Acrolein co-treated with methacrylaldehyde co-treated with Ozone results in decreased expression of SLC29A1 mRNA			[53]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Air Pollutants results in increased abundance of Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone which results in decreased expression of SLC29A1 mRNA			[52]
Regulation Mechanism				Transcription Factor Info
afuresertib	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	afuresertib results in decreased expression of SLC29A1 mRNA			[57]
Regulation Mechanism				Transcription Factor Info
alpha-pinene	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone results in decreased expression of SLC29A1 mRNA			[52]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Air Pollutants results in increased abundance of Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone which results in decreased expression of SLC29A1 mRNA			[52]
Regulation Mechanism				Transcription Factor Info
aristolochic acid I	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	aristolochic acid I results in decreased expression of SLC29A1 mRNA			[58]
Regulation Mechanism				Transcription Factor Info
Arsenic Trioxide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Tretinoin co-treated with Arsenic Trioxide results in increased expression of SLC29A1 mRNA			[60]
Regulation Mechanism				Transcription Factor Info
benzyloxycarbonylleucyl-leucyl-leucine aldehyde	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SLC29A1 mRNA			[42]
Regulation Mechanism				Transcription Factor Info
beta-lapachone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	beta-lapachone results in increased expression of SLC29A1 mRNA			[62]
Regulation Mechanism				Transcription Factor Info
bisphenol A	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	bisphenol A affects the expression of SLC29A1 mRNA			[41]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	bisphenol A co-treated with Fulvestrant results in decreased methylation of SLC29A1 gene			[63]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	bisphenol A results in decreased expression of SLC29A1 protein			[64]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	bisphenol A results in decreased methylation of SLC29A1 gene			[63]
Regulation Mechanism				Transcription Factor Info
bisphenol S	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	bisphenol S results in decreased methylation of SLC29A1 gene			[63]
Regulation Mechanism				Transcription Factor Info
Cadmium Chloride	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cadmium Chloride results in decreased expression of SLC29A1 mRNA			[65]
Regulation Mechanism				Transcription Factor Info
CGP 52608	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	CGP 52608 promotes the reaction RORA protein binds to SLC29A1 gene			[67]
Regulation Mechanism				Transcription Factor Info
Cilostazol	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cilostazol inhibits the reaction 4-nitrobenzylthioinosine binds to SLC29A1 protein			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Cilostazol inhibits the reaction SLC29A1 protein results in increased uptake of Adenosine			[47]
Regulation Mechanism				Transcription Factor Info
cobaltous chloride	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	cobaltous chloride results in decreased expression of SLC29A1 mRNA			[69]
Regulation Mechanism				Transcription Factor Info
Copper	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	NSC 689534 binds to Copper which results in decreased expression of SLC29A1 mRNA			[70]
Regulation Mechanism				Transcription Factor Info
coumarin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	coumarin results in increased phosphorylation of SLC29A1 protein			[66]
Regulation Mechanism				Transcription Factor Info
Cytarabine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC29A1 gene polymorphism results in decreased susceptibility to Cytarabine			[71]
Regulation Mechanism				Transcription Factor Info
deoxynivalenol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	deoxynivalenol results in decreased expression of SLC29A1 protein			[72]
Regulation Mechanism				Transcription Factor Info
Dichlorodiphenyl Dichloroethylene	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Dichlorodiphenyl Dichloroethylene results in increased expression of SLC29A1 mRNA			[73]
Regulation Mechanism				Transcription Factor Info
Diethylhexyl Phthalate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Diethylhexyl Phthalate results in increased abundance of mono-(2-ethylhexyl)phthalate which results in increased methylation of SLC29A1 3' UTR			[74]
Regulation Mechanism				Transcription Factor Info
Dilazep	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Dilazep inhibits the reaction SLC29A1 protein results in increased uptake of Uridine			[50]
Regulation Mechanism				Transcription Factor Info
dorsomorphin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased expression of SLC29A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
draflazine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	draflazine inhibits the reaction 4-nitrobenzylthioinosine binds to SLC29A1 protein			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	draflazine inhibits the reaction SLC29A1 protein results in increased uptake of Adenosine			[47]
Regulation Mechanism				Transcription Factor Info
Ethanol	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ethanol promotes the reaction SLC29A1 protein alternative form results in increased uptake of Adenosine			[54]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Ethanol promotes the reaction SLC29A1 protein results in increased uptake of Adenosine			[54]
Regulation Mechanism				Transcription Factor Info
fialuridine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC29A1 affects the susceptibility to fialuridine			[78]
Regulation Mechanism				Transcription Factor Info
Fulvestrant	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	bisphenol A co-treated with Fulvestrant results in decreased methylation of SLC29A1 gene			[63]
Regulation Mechanism				Transcription Factor Info
Gemcitabine	8 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	4-nitrobenzylthioinosine inhibits the reaction SLC29A1 protein results in increased uptake of Gemcitabine			[49]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Fluorouracil promotes the reaction SLC29A1 protein results in increased uptake of Gemcitabine			[26]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	S 1 (combination) results in increased expression of SLC29A1 mRNA which results in increased uptake of Gemcitabine			[7]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	SLC29A1 mRNA results in increased susceptibility to Gemcitabine			[80]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	SLC29A1 protein affects the susceptibility to Gemcitabine			[76]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	SLC29A1 protein results in decreased susceptibility to Gemcitabine			[49]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	SLC29A1 protein results in increased susceptibility to Gemcitabine			[81]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	SLC29A1 protein results in increased uptake of Gemcitabine			[26]
Regulation Mechanism				Transcription Factor Info
ICG 001	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	ICG 001 results in decreased expression of SLC29A1 mRNA			[36]
Regulation Mechanism				Transcription Factor Info
methacrylaldehyde	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone results in decreased expression of SLC29A1 mRNA			[52]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Acrolein co-treated with methacrylaldehyde co-treated with Ozone results in decreased expression of SLC29A1 mRNA			[53]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Air Pollutants results in increased abundance of Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone which results in decreased expression of SLC29A1 mRNA			[52]
Regulation Mechanism				Transcription Factor Info
methyleugenol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	methyleugenol results in increased expression of SLC29A1 mRNA			[43]
Regulation Mechanism				Transcription Factor Info
Methylthioinosine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC29A1 mRNA affects the transport of Methylthioinosine			[83]
Regulation Mechanism				Transcription Factor Info
mono-(2-ethylhexyl)phthalate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Diethylhexyl Phthalate results in increased abundance of mono-(2-ethylhexyl)phthalate which results in increased methylation of SLC29A1 3' UTR			[74]
Regulation Mechanism				Transcription Factor Info
Mustard Gas	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Mustard Gas results in decreased expression of SLC29A1 mRNA			[84]
Regulation Mechanism				Transcription Factor Info
NSC 689534	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	NSC 689534 binds to Copper which results in decreased expression of SLC29A1 mRNA			[70]
Regulation Mechanism				Transcription Factor Info
Okadaic Acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Okadaic Acid results in increased expression of SLC29A1 mRNA			[85]
Regulation Mechanism				Transcription Factor Info
Ozone	5 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone results in decreased expression of SLC29A1 mRNA			[52]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Acrolein co-treated with methacrylaldehyde co-treated with Ozone results in decreased expression of SLC29A1 mRNA			[53]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Air Pollutants results in increased abundance of Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone which results in decreased expression of SLC29A1 mRNA			[52]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Air Pollutants results in increased abundance of Ozone which affects the expression of SLC29A1 mRNA			[86]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Volatile Organic Compounds co-treated with Ozone results in decreased expression of SLC29A1 mRNA			[52]
Regulation Mechanism				Transcription Factor Info
Ribavirin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC29A1 protein results in increased uptake of Ribavirin			[87]
Regulation Mechanism				Transcription Factor Info
S 1 (combination)	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	S 1 (combination) results in increased expression of SLC29A1 mRNA			[7]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	S 1 (combination) results in increased expression of SLC29A1 mRNA which results in increased uptake of Gemcitabine			[7]
Regulation Mechanism				Transcription Factor Info
Selenium	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Selenium co-treated with Vitamin E results in increased expression of SLC29A1 mRNA			[28]
Regulation Mechanism				Transcription Factor Info
seocalcitol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	seocalcitol results in decreased expression of SLC29A1 mRNA			[25]
Regulation Mechanism				Transcription Factor Info
sodium arsenite	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	sodium arsenite results in decreased expression of SLC29A1 mRNA			[73]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	sodium arsenite results in increased expression of SLC29A1 mRNA			[44]
Regulation Mechanism				Transcription Factor Info
Thiram	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Thiram results in decreased expression of SLC29A1 mRNA			[73]
Regulation Mechanism				Transcription Factor Info
triphenyl phosphate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	triphenyl phosphate affects the expression of SLC29A1 mRNA			[88]
Regulation Mechanism				Transcription Factor Info
UFT(R) drug	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	UFT(R) drug results in increased expression of SLC29A1 mRNA			[26]
Regulation Mechanism				Transcription Factor Info
Vinorelbine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC29A1 protein affects the susceptibility to Vinorelbine			[76]
Regulation Mechanism				Transcription Factor Info
Approved Drug
Adenosine	9 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Adenosine inhibits the transportation of Uridine by SLC29A1			[3]
Affected Drug/Substrate	Uridine	Modulation Type	Inhibition
Dipyridamole	6 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Dipyridamole inhibits the activity of SLC29A1			[5], [6]
Cell System	Myelogenous leukemia cell line (K562)-ENT1
Lidoflazine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Lidoflazine inhibits the activity of SLC29A1			[6]
Cell System	Myelogenous leukemia cell line (K562)-ENT1
Fluorouracil	5 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Fluorouracil increases the expression of SLC29A1			[7]
Copper Sulfate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Copper Sulfate inhibits the expression of SLC29A1			[8]
Calcitriol	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Calcitriol inhibits the expression of SLC29A1			[9]
Testosterone	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Testosterone inhibits the expression of SLC29A1			[9]
Acetaminophen	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Acetaminophen increases the expression of SLC29A1			[10]
Vincristine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Vincristine inhibits the expression of SLC29A1			[11]
Tretinoin	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Tretinoin inhibits the expression of SLC29A1			[12]
Valproic Acid	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Valproic Acid inhibits the expression of SLC29A1			[13]
Rifampin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Rifampin increases the expression of SLC29A1			[14]
Cisplatin	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cisplatin inhibits the expression of SLC29A1			[15]
Urethane	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Urethane increases the expression of SLC29A1			[16]
Doxorubicin	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Doxorubicin affects the expression of SLC29A1			[17]
Sunitinib	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Sunitinib increases the expression of SLC29A1			[19]
Estradiol	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Estradiol increases the expression of SLC29A1			[20]
Cyclosporine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cyclosporine inhibits the expression of SLC29A1			[21]
Uridine	9 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Uridine inhibits the activity of SLC29A1			[3]
Ticagrelor	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ticagrelor inhibits the activity of SLC29A1			[22]
Sulindac	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Sulindac inhibits the activity of SLC29A1			[23]
Zidovudine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Zidovudine increases the expression of SLC29A1			[24]
Regulation Mechanism	via modulation of Zinc finger protein SNAI1 (SNAI1)			Transcription Factor Info
Affected Drug/Substrate	Gemcitabine	Modulation Type	Inducer
Cell System	Human pancreatic cancer cells cells (PK1)
Drug Marketed but not Approved by US FDA
Demecolcine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Demecolcine inhibits the expression of SLC29A1			[11]
Rotenone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Rotenone increases the expression of SLC29A1			[18]
Drug in Phase 3 Trial
Seocalcitol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Seocalcitol inhibits the expression of SLC29A1			[25]
Vitamin E	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Vitamin E increases the expression of SLC29A1			[28]
Triclosan	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Triclosan inhibits the expression of SLC29A1			[40]
Drug in Phase 2 Trial
Bisphenol A	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Bisphenol A affects the expression of SLC29A1			[41]
Drug in Phase 1 Trial
Tegafur-uracil	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Tegafur-uracil increases the expression of SLC29A1			[26]
Quercetin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Quercetin increases the expression of SLC29A1			[29]
Sodium arsenite	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Sodium arsenite increases the expression of SLC29A1			[44]
Drug in Preclinical Test
(+)-JQ1	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	(+)-JQ1 inhibits the expression of SLC29A1			[33]
Discontinued Drug
Tecadenoson	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Tecadenoson inhibits the transportation of Uridine by SLC29A1			[3]
Affected Drug/Substrate	Uridine	Modulation Type	Inhibition
Investigative Drug
6-Benzylthioinosine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	6-Benzylthioinosine inhibits the transportation of 4-Nitrobenzylthioinosine by SLC29A1			[1]
Affected Drug/Substrate	4-Nitrobenzylthioinosine	Modulation Type	Inhibition
DT Modulation2	6-Benzylthioinosine inhibits the activity of SLC29A1			[2]
N6-cyclopentyladenosine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	N6-cyclopentyladenosine inhibits the transportation of 4-Nitrobenzylthioinosine by SLC29A1			[1]
Affected Drug/Substrate	4-Nitrobenzylthioinosine	Modulation Type	Inhibition
Phlorizin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Phlorizin inhibits the transportation of Uridine by SLC29A1			[4]
Affected Drug/Substrate	Uridine	Modulation Type	Inhibition
Coumestrol	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Coumestrol increases the expression of SLC29A1			[27]
MG-132	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	MG-132 increases the expression of SLC29A1			[42]
Patented Pharmaceutical Agent
ICG-001	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	ICG-001 inhibits the expression of SLC29A1			[36]
GSK-J4	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	GSK-J4 inhibits the expression of SLC29A1			[39]
Natural Product
Particulate Matter	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Particulate Matter inhibits the expression of SLC29A1			[38]
Methyleugenol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Methyleugenol increases the expression of SLC29A1			[43]
Tobacco Smoke Pollution	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Tobacco Smoke Pollution inhibits the expression of SLC29A1			[45]
Caffeine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Caffeine results in decreased phosphorylation of SLC29A1 protein			[66]
Regulation Mechanism				Transcription Factor Info
Traditional Medicine
Jinfukang	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Jinfukang increases the expression of SLC29A1			[37]
Plant Extract
Plant Extracts	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Plant Extracts inhibits the expression of SLC29A1			[32]
Mycotoxins
Aflatoxin B1	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Aflatoxin B1 increases the expression of SLC29A1			[43]
DT Modulation2	Aflatoxin B1 affects the expression of SLC29A1 protein			[55]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Aflatoxin B1 results in decreased methylation of SLC29A1 gene			[56]
Regulation Mechanism				Transcription Factor Info
Acute Toxic Substance
Cadmium	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cadmium inhibits the expression of SLC29A1			[31]
Carcinogen
Benzo(a)pyrene	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Benzo(a)pyrene increases the expression of SLC29A1			[43]
Arsenic	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Arsenic affects the methylation of SLC29A1 gene			[59]
Regulation Mechanism				Transcription Factor Info
Health and Environmental Toxicant
1-methyl-4-phenylpyridinium	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	1-methyl-4-phenylpyridinium increases the expression of SLC29A1			[34]
tris(1,3-dichloro-2-propyl)phosphate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC29A1			[35]
Herbicide
Atrazine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Atrazine increases the expression of SLC29A1			[30]

References
1	Inhibition of nucleoside transport proteins by C8-alkylamine-substituted purines. J Med Chem. 2005 Jan 13;48(1):321-9.
2	CoMFA and CoMSIA 3D-QSAR studies on S(6)-(4-nitrobenzyl)mercaptopurine riboside (NBMPR) analogs as inhibitors of human equilibrative nucleoside transporter 1 (hENT1). Bioorg Med Chem Lett. 2009 Jan 15;19(2):314-8.
3	Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1. Drug Metab Dispos. 2013 Apr;41(4):916-22.
4	Synthesis and biological evaluation of phloridzin analogs as human concentrative nucleoside transporter 3 (hCNT3) inhibitors. Bioorg Med Chem Lett. 2009 Feb 1;19(3):917-21.
5	Novel halogenated nitrobenzylthioinosine analogs as es nucleoside transporter inhibitors. Bioorg Med Chem Lett. 2004 May 3;14(9):2257-60.
6	Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibitors. J Med Chem. 2007 Aug 9;50(16):3906-20.
7	Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts. Anticancer Res. 2008 Jan-Feb;28(1A):179-86.
8	Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
9	Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
10	Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
11	Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
12	Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
13	A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
14	Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
15	Low Doses of Cisplatin Induce Gene Alterations, Cell Cycle Arrest, and Apoptosis in Human Promyelocytic Leukemia Cells. Biomark Insights. 2016 Aug 24;11:113-21.
16	Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
17	Bringing in vitro analysis closer to in vivo: Studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
18	Toxicity, recovery, and resilience in a 3D dopaminergic neuronal in vitro model exposed to rotenone. Arch Toxicol. 2018 Aug;92(8):2587-2606.
19	Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761.
20	17 beta-Estradiol Activates HSF1 via MAPK Signaling in ER alpha-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533.
21	Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
22	Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study. Platelets. 2019;30(5):579-588.
23	Physiological and pharmacological roles of vascular nucleoside transporters. J Cardiovasc Pharmacol. 2012 Jan;59(1):10-5.
24	Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3beta-Snail pathway. Cell Death Dis. 2015 Jun 25;6(6):e1795.
25	Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol. 2002 Jun;16(6):1243-56.
26	Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model. Pancreas. 2006 Aug;33(2):142-7.
27	Pleiotropic combinatorial transcriptomes of human breast cancer cells exposed to mixtures of dietary phytoestrogens. Food Chem Toxicol. 2009 Apr;47(4):787-95.
28	Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
29	Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
30	Endoplasmic reticulum stress impairs insulin signaling through mitochondrial damage in SH-SY5Y cells. Neurosignals. 2012;20(4):265-80.
31	Short and long term gene expression variation and networking in human proximal tubule cells when exposed to cadmium. BMC Med Genomics. 2013;6 Suppl 1(Suppl 1):S2.
32	Ethanol extract of Hedyotis diffusa willd upregulates G0/G1 phase arrest and induces apoptosis in human leukemia cells by modulating caspase cascade signaling and altering associated genes expression was assayed by cDNA microarray. Environ Toxicol. 2015 Sep;30(10):1162-77.
33	Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014 May 15;5(9):2355-71.
34	Transcriptional and metabolic adaptation of human neurons to the mitochondrial toxicant MPP(+). Cell Death Dis. 2014 May 8;5(5):e1222.
35	Defensive and adverse energy-related molecular responses precede tris (1, 3-dichloro-2-propyl) phosphate cytotoxicity. J Appl Toxicol. 2016 May;36(5):649-58.
36	Altering cancer transcriptomes using epigenomic inhibitors. Epigenetics Chromatin. 2015 Feb 24;8:9.
37	Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
38	Diesel exhaust particulate associated chemicals attenuate expression of CXCL10 in human primary bronchial epithelial cells. Toxicol In Vitro. 2017 Dec;45(Pt 3):409-416.
39	Inhibition of histone H3K27 demethylases selectively modulates inflammatory phenotypes of natural killer cells. J Biol Chem. 2018 Feb 16;293(7):2422-2437.
40	Transcriptome and DNA Methylome Dynamics during Triclosan-Induced Cardiomyocyte Differentiation Toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
41	Comprehensive analysis of transcriptomic changes induced by low and high doses of bisphenol A in HepG2 spheroids in vitro and rat liver in vivo. Environ Res. 2019 Jun;173:124-134.
42	Proteasome inhibition creates a chromatin landscape favorable to RNA Pol II processivity. J Biol Chem. 2020 Jan 31;295(5):1271-1287.
43	Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297.
44	Dynamic alteration in miRNA and mRNA expression profiles at different stages of chronic arsenic exposure-induced carcinogenesis in a human cell culture model of skin cancer. Arch Toxicol. 2021 Jul;95(7):2351-2365.
45	Integration of transcriptome analysis with pathophysiological endpoints to evaluate cigarette smoke toxicity in an in vitro human airway tissue model. Arch Toxicol. 2021 May;95(5):1739-1761.
46	Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
47	A semi-quantitative translational pharmacology analysis to understand the relationship between in vitro ENT1 inhibition and the clinical incidence of dyspnoea and bronchospasm. Toxicol Appl Pharmacol. 2017;317:41-50.
48	Nucleoside transport in human colonic epithelial cell lines: evidence for two Na+-independent transport systems in T84 and Caco-2 cells. Biochim Biophys Acta. 1999;1419(1):15-22.
49	Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer. Anticancer Res. 2007 Jul-Aug;27(4B):2241-9.
50	Molecular cloning and functional characterization of nitrobenzylthioinosine (NBMPR)-sensitive (es) and NBMPR-insensitive (ei) equilibrative nucleoside transporter proteins (rENT1 and rENT2) from rat tissues. J Biol Chem. 1997;272(45):28423-30.
51	Integration of transcriptomics, proteomics and metabolomics data to reveal the biological mechanisms of abrin injury in human lung epithelial cells. Toxicol Lett. 2019;312:1-10.
52	Post-transcriptional air pollution oxidation to the cholesterol biosynthesis pathway promotes pulmonary stress phenotypes. Commun Biol. 2020;3(1):392.
53	Understanding the Functional Impact of VOC-Ozone Mixtures on the Chemistry of RNA in Epithelial Lung Cells. Res Rep Health Eff Inst. 2020;2020(201).
54	Functional role of the polymorphic 647 T/C variant of ENT1 (SLC29A1) and its association with alcohol withdrawal seizures. PLoS One. 2011;6(1):e16331.
55	Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
56	Aflatoxin B1 induces persistent epigenomic effects in primary human hepatocytes associated with hepatocellular carcinoma. Toxicology. 2016 Mar 28;350-352:31-9.
57	Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Cancer Med. 2017;6(11):2646-2659.
58	Integration of transcriptomic, proteomic and metabolomic data to reveal the biological mechanisms of AAI injury in renal epithelial cells. Toxicol In Vitro. 2021;70:105054.
59	Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106.
60	Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005;102(21):7653-8.
61	Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017;8(1):1369-1391.
62	Lapachone induces ferroptosis of colorectal cancer cells via NCOA4-mediated ferritinophagy by activating JNK pathway. Chem Biol Interact. 2024;389:110866.
63	DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019;11(1):138.
64	Low-dose Bisphenol A exposure alters the functionality and cellular environment in a human cardiomyocyte model. Environ Pollut. 2023;335:122359.
65	Evaluation of Cd-induced cytotoxicity in primary human keratinocytes. Hum Exp Toxicol. 2024;43:9603271231224458.
66	Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022;449:116110.
67	Identification of potential target genes of ROR-alpha in THP1 and HUVEC cell lines. Exp Cell Res. 2017;353(1):6-15.
68	Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer. Br J Cancer. 2008;99(5):760-7.
69	Transcription and splicing regulation in human umbilical vein endothelial cells under hypoxic stress conditions by exon array. BMC Genomics. 2009;10:126.
70	A copper chelate of thiosemicarbazone NSC 689534 induces oxidative/ER stress and inhibits tumor growth in vitro and in vivo. Free Radic Biol Med. 2011 Jan 1;50(1):110-21.
71	Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells. Cancer Res. 2008;68(7):2349-57.
72	Alterations in the proteomes of HepG2 and IHKE cells inflicted by six selected mycotoxins. Arch Toxicol. 2025;99(2):701-715.
73	High-Throughput Transcriptomics of Nontumorigenic Breast Cells Exposed to Environmentally Relevant Chemicals. Environ Health Perspect. 2024;132(4):47002.
74	Effect of prenatal exposure to phthalates on epigenome-wide DNA methylations in cord blood and implications for fetal growth: The Hokkaido Study on Environment and Children's Health. Sci Total Environ. 2021;783:147035.
75	New role of the human equilibrative nucleoside transporter 1 (hENT1) in epithelial-to-mesenchymal transition in renal tubular cells. J Cell Physiol. 2012;227(4):1521-8.
76	High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study. Leuk Lymphoma. 2008;49(6):1202-5.
77	Transforming growth factor beta1 targets estrogen receptor signaling in bronchial epithelial cells. Respir Res. 2018 Aug 30;19(1):160.
78	Mechanisms of Chronic Fialuridine Hepatotoxicity as Revealed in Primary Human Hepatocyte Spheroids. Toxicol Sci. 2019;171(2):385-395.
79	Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006;118(7):1699-712.
80	Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma. Lab Invest. 2008;88(7):773-84.
81	The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res. 2004;10(20):6956-61.
82	Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive (ei) equilibrative nucleoside transporter from human placenta. Biochem J. 1997;328 ( Pt 3)(Pt 3):739-43.
83	Molecular mechanisms underlying the enhanced sensitivity of thiopurine-resistant T-lymphoblastic cell lines to methyl mercaptopurineriboside. Biochem Pharmacol. 2006;72(7):816-23.
84	Whole genome expression analysis in primary bronchial epithelial cells after exposure to sulphur mustard. Toxicol Lett. 2014;230(3):393-401.
85	A multi-omics approach to elucidate okadaic acid-induced changes in human HepaRG hepatocarcinoma cells. Arch Toxicol. 2024;98(9):2919-2935.
86	Ozone exposure and blood transcriptome: A randomized, controlled, crossover trial among healthy adults. Environ Int. 2022;163:107242.
87	Characterization of ribavirin uptake systems in human hepatocytes. J Hepatol. 2010 Apr;52(4):486-92.
88	Association between Organophosphate Ester Exposure and Insulin Resistance with Glycometabolic Disorders among Older Chinese Adults 60-69 Years of Age: Evidence from the China BAPE Study. Environ Health Perspect. 2023;131(4):47009.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.

Detail Information of Exogenous Modulation

Visitor Map

Correspondence